As­traZeneca push­es Tagris­so-chemo com­bo fol­low­ing pos­i­tive pro­gres­sion-free sur­vival da­ta

As­traZeneca’s EGFR in­hibitor Tagris­so (os­imer­tinib) could be on its way to adding an­oth­er lung can­cer in­di­ca­tion af­ter the com­pa­ny said on Tues­day the drug plus chemo showed sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful im­prove­ment in pro­gres­sion-free sur­vival com­pared to Tagris­so as a monother­a­py in late-stage lung can­cer pa­tients.

In the Phase III FLAU­RA2 tri­al, As­traZeneca test­ed out a Tagris­so-chemo com­bo in late-stage pa­tients with lo­cal­ly ad­vanced or metasta­t­ic EGFR-mu­tat­ed non-small cell lung can­cer (NSCLC). Though no da­ta were pro­vid­ed, the pri­ma­ry end­point, pro­gres­sion-free sur­vival, was sta­tis­ti­cal­ly sig­nif­i­cant, ac­cord­ing to As­traZeneca.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER